Monoaminergic drugs for motor recovery after ischemic stroke
| Autor: | Blandine Acket, V. Sattler, Nicolas Raposo, J. Tardy, Jean-François Albucher, Isabelle Loubinoux, François Chollet, J. Pariente |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Médicaments monoaminergiques Monoaminergic drugs Spontaneous recovery Pharmacotherapy Neuroimaging Recovery Fluoxetine Neuroplasticity Monoaminergic medicine Humans Ischémie cérébrale Orthopedics and Sports Medicine Intensive care medicine Fluoxétine Stroke Brain plasticity Plasticité cérébrale Neuronal Plasticity Rehabilitation Recovery of Function Human brain Récupération fonctionnelle medicine.disease medicine.anatomical_structure Psychology Neuroscience Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | Annals of Physical and Rehabilitation Medicine. 57:509-519 |
| ISSN: | 1877-0657 |
| DOI: | 10.1016/j.rehab.2014.08.002 |
| Popis: | Today, administering rTPA thrombolytic therapy within the first hours of a stroke is the only validated drug therapy for improving the spontaneous – and most of the time incomplete – recovery of neurological functions post-stroke. However in the past decade, thanks in part to the considerable advances of neuroimaging techniques, we have learned that spontaneous recovery of neurological functions was associated with a wide intracerebral reorganization of the damaged human brain. The question of whether lesioned-brain plasticity can be modulated by external factors like pharmacological agents is now addressed in the hope of improving recovery and reducing the chronic impairments of stroke patients. In this paper, we review the preclinical and clinical evidence for a direct action of SSRIs in promoting recovery in ischemic stroke patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect